Science

Liu-Jun Xue, MD, Xiao-Zhong Yang, MD, PhD, Qiang Tong, MD, Peng Shen, MD, Shi-Jie Ma, MD, Shang-Nong Wu, MD, Jin-Long Zheng, MD, PhD, Hong-Gang Wang, MD

Imbalances in the gut microbiota mediate the progression of neurodegenerative diseases such as Parkinson’s disease (PD). Fecal
microbiota transplantation (FMT) is currently being explored as a potential therapy for PD. The objective of this study was to assess the efficacy and safety of FMT on PD. Fifteen PD patients were included, 10 of them received FMT via colonoscopy (colonic FMT group) and 5 received FMT via nasal-jejunal tube (nasointestinal FMT group). The score of PSQI, HAMD, HAMA, PDQ-39, NMSQ and UPDRS-III significantly decreased after FMT treatment (all P less than .05). Colonic FMT group showed significant improvement and longer maintenance of efficacy compared with nasointestinal FMT (P=.002). Two patients achieved self-satisfying outcomes that last for more than 24 months. However, nasointestinal FMT group had no significant therapeutic effect, although UPDRS-III score slightly reduced. There were no patients were satisfied with nasointestinal FMT for more than 3 months. Among 15 PD patients, there were 5 cases had adverse events (AEs), including diarrhea (2 cases), abdominal pain (2 cases) and flatulence (1 case). These AEs were mild and self-limiting. We conclude that FMT can relieve the motor and non-motor symptoms with acceptable safety in PD. Compared with nasointestinal FMT, colonic FMT seems better and preferable.